BioXcel Therapeutics Inc (BTAI) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $0.08 (+12.26%), Market cap $0.03B, 52-week low–high $1.02 ~ $6.80.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid
Financial statements, price targets, institutional (13F) holdings and related news for BioXcel Therapeutics Inc are updated in real time on BlackAll Trade.
BioXcel Therapeutics Inc trades at $0.08 (+12.26%). Real-time quotes and charts are available on BlackAll Trade.
BioXcel Therapeutics Inc has a market cap of about $0.03B.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in n